In a report released today, Matthew Harrison from Morgan Stanley maintained a Buy rating on Argenx Se (ARGX), with a price target of $311.00. The company’s shares closed last Wednesday at $296.21, close to its 52-week high of $297.64.
According to TipRanks.com, Harrison is a 5-star analyst with an average return of 22.2% and a 62.6% success rate. Harrison covers the Healthcare sector, focusing on stocks such as Biohaven Pharmaceutical Holding Co, Global Blood Therapeutics, and Zentalis Pharmaceuticals.
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Argenx Se with a $283.57 average price target, a -6.1% downside from current levels. In a report issued on December 3, Stifel Nicolaus also maintained a Buy rating on the stock with a $318.00 price target.
See today’s analyst top recommended stocks >>
The company has a one-year high of $297.64 and a one-year low of $103.75. Currently, Argenx Se has an average volume of 159.9K.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
argenx SE is a clinical-stage biotechnology company, which engages in the development of antibody-based therapies for the treatment of autoimmune diseases and cancer. Its products include ARGX-113 for the treatment of autoimmune disease myasthenia gravis and ARGX-110 for the treatment of hematological cancer acute myeloid leukemia. The company was founded by Hans J. W. de Haard, Torsten Dreier, and Tim van Hauwermeiren on April 25, 2008 and is headquartered in Breda, the Netherlands.
